Small Cap📈 NASDAQ: ABUS
Arbutus Biopharma Corporation (NASDAQ: ABUS)
Published 29 January 2026US Equity Report
Arbutus Biopharma Corporation
NASDAQ: ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
US Equity Report
A$5000.00
Already a subscriber?
Sign in to read this report.
Required subscription
US Equity Report
Expand beyond the ASX with expert research on carefully selected U.S. stocks, covering market leaders, emerging opportunities, and global investment trends.
- ✓ U.S. Stock Research & Analysis
- ✓ Delivered every Friday
- ✓ Company & Industry Analysis
- ✓ Full Historical Report Access
A$5000.00/ 12 months
Risk:Medium
Subscribe Now →
